University of Chicago Medicine, Section of Cardiology, Chicago, Illinois.
University of California-Los Angeles, Division of Cardiology, Los Angeles, California.
J Card Fail. 2021 Oct;27(10):1045-1052. doi: 10.1016/j.cardfail.2021.05.010. Epub 2021 May 25.
Right heart catheterization for invasive hemodynamics has shown only modest correlation with clinical outcomes. We designed a novel hemodynamic variable that incorporates ventricular output and filling pressure. We anticipated that the aortic pulsatility index (API) would correlate with clinical outcomes in patients with heart failure.
We retrospectively analyzed consecutive patients undergoing right heart catheterization with milrinone drug study at our institution (February 2013 to November 2019). The API was calculated as (systolic blood pressure - diastolic blood pressure)/pulmonary capillary wedge pressure. The primary outcome was freedom from advanced therapies, defined as the need for inotropes, temporary mechanical circulatory support, a left ventricular assist device, or orthotopic heart transplantation, or death at 30 days. A total of 224 patient encounters, age 57 years (48-66 years; 34% women; 31% ischemic cardiomyopathy) were included. In univariable analysis, lower baseline API was significantly associated with progression to advanced therapies or death at 30-days (odds ratio 0.43, 95% confidence interval 0.30-0.61; P < .001) compared with those on continued medical management. Receiver operator characteristic analysis specified an optimal cutpoint of 1.45 for API. A Kaplan-Meier analysis indicated an association of API with the primary outcome (79% for API ≥ 1.45 vs 48% for API < 1.45). In multivariable analysis, higher API was strongly associated with freedom from advanced therapies or death (odds ratio 0.38, 95% confidence interval 0.22-0.65, P ≤ .001), even when adjusted for baseline characteristics and routine right heart catheterization measurements.
The API is a novel invasive hemodynamic measurement that is associated independently with freedom from advanced therapies or death at 30-day follow-up.
右心导管术用于侵入性血液动力学检查,仅与临床结果有适度相关性。我们设计了一种新的血液动力学变量,该变量结合了心输出量和充盈压。我们预计主动脉脉动指数(API)与心力衰竭患者的临床结果相关。
我们回顾性分析了在我院接受右心导管术并接受米力农药物研究的连续患者(2013 年 2 月至 2019 年 11 月)。API 计算为(收缩压-舒张压)/肺毛细血管楔压。主要结果是无高级治疗,定义为需要正性肌力药、临时机械循环支持、左心室辅助装置或原位心脏移植,或 30 天内死亡。共纳入 224 例患者,年龄 57 岁(48-66 岁;34%为女性;31%为缺血性心肌病)。单变量分析显示,基线时 API 较低与 30 天内进展为高级治疗或死亡显著相关(优势比 0.43,95%置信区间 0.30-0.61;P<0.001),而与继续药物治疗者相比。受试者工作特征分析指定 API 的最佳切点为 1.45。Kaplan-Meier 分析表明 API 与主要结果相关(API≥1.45 的患者为 79%,API<1.45 的患者为 48%)。多变量分析显示,API 与无高级治疗或死亡的几率呈负相关(优势比 0.38,95%置信区间 0.22-0.65,P≤0.001),即使在调整了基线特征和常规右心导管术测量后也是如此。
API 是一种新的侵入性血液动力学测量方法,与 30 天随访时无高级治疗或死亡独立相关。